Item 7.01 Regulation FD Disclosure.

On December 06, 2022, Emergent BioSolutions Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration accepted for Priority Review its supplemental New Drug Application for NARCAN® (naloxone HCl) Nasal Spray, 4mg as an over-the-counter emergency treatment for known or suspected opioid overdose. A copy of the Company's press release is attached hereto as Exhibit 99.1.

The information contained in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

Exhibit No.                                              Description
99.1                       Press release issued by Emergent BioSolutions Inc. on December 06,
                         2022.
104                      Cover Page Interactive Data File (embedded within the Inline XBRL
                         document).

© Edgar Online, source Glimpses